2-Bromo-LSD


Non-hallucinogenic lysergamide serotonin receptor modulator with biased 5-HT2A partial agonism and 5-HT1 pan-agonism

A brominated lysergic acid diethylamide derivative originally synthesized by Hofmann and Troxler in 1957, distinguished from the parent compound LSD by non-hallucinogenic biased partial agonism at the serotonin 5-HT2A receptor, antagonism at the cardiotoxicity-associated 5-HT2B receptor, potent 5-HT1 pan-agonism, and emerging therapeutic interest in cluster headache prophylaxis and rapid-acting antidepressant development.

Abstract

2-Bromo-lysergic acid diethylamide (2-Br-LSD; BOL-148; CAS 478-84-2), the 2-bromo derivative of lysergic acid diethylamide (LSD), is a non-hallucinogenic lysergamide serotonin receptor modulator first synthesized by Franz Troxler and Albert Hofmann at Sandoz in 1957 as part of a systematic structure-activity exploration of ergoline pharmacology. The compound binds with high affinity to the same serotonin, dopamine, and adrenergic receptor targets as LSD but exhibits a fundamentally different functional profile: at the serotonin 5-HT2A receptor, 2-Br-LSD acts as a biased partial agonist with an Emax of approximately 60 percent of the serotonin reference response (compared to approximately 92 percent for LSD), weak beta-arrestin recruitment (Emax approximately 37 percent), and no induction of the head-twitch response in mice across a 100-fold dose range, the accepted rodent behavioral proxy for human hallucinogenic activity. At the serotonin 5-HT2B receptor, 2-Br-LSD acts as an antagonist, eliminating the cardiac valvulopathy liability that constrains chronic dosing of LSD and other ergoline agonists at this target. Across the 5-HT1 receptor family (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), the compound demonstrates potent pan-agonism, engaging the established anti-migraine drug targets 5-HT1B, 5-HT1D, and 5-HT1F at sub-nanomolar to low-nanomolar functional concentrations.

The therapeutic interest in 2-Br-LSD spans two principal domains. The second is rapid-acting antidepressant activity, supported by the Lewis et al. (2023) characterization in Cell Reports demonstrating that 2-Br-LSD promotes dendritogenesis and spinogenesis in primary rat cortical neurons at 1 to 10 micromolar concentrations (comparable to ketamine), reverses chronic variable stress-induced behavioral deficits in mice with effects persisting at least 28 days after a four-dose regimen, and does so through a 5-HT2A-dependent mechanism confirmed by volinanserin blockade both in vitro and in vivo. The compound does not produce tolerance on seven-day repeated dosing, in contrast to classical psychedelics that produce rapid tachyphylaxis.

Multiple pharmaceutical development programs are active. BetterLife Pharma is advancing BETR-001 (2-Br-LSD) through IND-enabling studies for major depressive disorder and cluster headache, with FDA pre-IND feedback received in January 2022 confirming suitability of the development program for IND filing. Seaport Therapeutics is developing SPT-348 (Glyph2BLSD), an oral prodrug of 2-Br-LSD, for treatment-resistant depression and post-traumatic stress disorder, with first-in-human-enabling studies underway. Cryo-electron microscopy structures of the 5-HT2A receptor bound to 2-Br-LSD in complex with mini-Gq protein (PDB 9AS0; Gumpper, Fay, Roth) have elucidated the structural basis of its biased partial agonism and provide a molecular template for next-generation non-hallucinogenic psychoplastogen design.

Pharmacokinetics in mice demonstrate rapid absorption (Tmax 0.2 hours in plasma, 0.17 hours in brain), brain penetrance (brain-to-plasma ratio 0.27 to 0.75), and short central nervous system residence (brain half-life 0.7 to 1.3 hours, below detection at 4 hours). The compound is not scheduled in the United States, Canada, Germany, or the European Union. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph